<DOC>
	<DOCNO>NCT01154335</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) combination OSI-906 everolimus treatment patient refractory metastatic colorectal cancer .</brief_summary>
	<brief_title>Everolimus OSI-906 Patients With Refractory Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Metastatic cancer colon rectum progress patient intolerant candidate : fluoropyrimidines , oxaliplatin , irinotecan , bevacizumab , cetuximab panitumumab . Testing Kras mutation perform ; Patients mutate wild type Kras eligible . ECOG PS 01 Life expectancy ≥ 3 month Adequate hematological function ANC 1500 , Platelets 100,000 , hemoglobin 9.0 AST , ALT Alk . Phos . ≤2.5 x ULN ≤5 x ULN know hepatic metastasis total bilirubin ≤1.5 ULN Serum creatinine ≤1.5 x ULN Fasting blood glucose &lt; 150 mg/dL Measurable disease accord RECIST 1.1 Able swallow whole pill INR ≤1.5 Anticoagulation allow LMW heparin Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fast triglyceride ≤2.5 x ULN ; If threshold exceed , patient include initiation lipid lower medication Patients receive cancer therapy &lt; 4 week 5 half life ( whichever short ) initiate study therapy Treatment investigational drug ≤ 4 week , 5 halflives drug , whichever short Patients require coumadin anticoagulation Patients major surgery significant traumatic injury ≤4 week study treatment Minor surgery ( exception port placement ) must complete ≤ 7days prior study therapy Previous treatment IGFR inhibitor MTOR Inhibitor Chronic , systemic treatment corticosteroid another immunosuppressive agent Patients QTc interval &gt; 450ms Patients require drug prolong QTc . Patients congenital long QT syndrome , history ventricular tachycardia , ventricular fibrillation , Torsades de Pointes bradycardia . Immunization attenuate live vaccine within 1 week begin study therapy study period ; Close contact anyone receive live virus vaccine avoid Meningeal brain metastasis Other malignancy &lt; 3 year , exception adequately treat basal squamous cell carcinoma skin , carcinoma situ cervix Patients know HIV Patients positive test hepatitis B C Patients risk factor hepatitis must test hepatitis viral loadHepatitis risk factor include follow : Lived Asia , Africa , Central South America , Eastern Europe , Spain , Portugal , Greece Any blood transfusion 1990 Any IV drug use Any dialysis Household contact Hep B infect patient Mother Hep B Highrisk sexual activity Body piercing/tattoos History suggestive hepatitis B Any severe uncontrolled condition could affect study participation : Severely impaired lung function ; DCLO ≤ 50 % normal predict value ; O² Sat &lt; 88 % rest room air Congestive Heart Failure NYHA Class III IV Unstable angina , symptomatic CHF , MI ≤ 6 month , serious uncontrolled cardiac arrhythmia clinically significant heart disease CVA , TIA , angioplasty , cardiac stenting &lt; 12 month Ventricular arrhythmia require medication Known history diabetes and/or patient require ongoing use insulin oral antihyperglycemic therapy Known liver disease Impairment GI function gastrointestinal disease may significantly alter absorption study drug Concurrent treatment drug strong CYP3A4 inducer moderate/strong CYP3A4 inhibitor Concurrent treatment drug strong CYP1A2 inhibitor inducer Women pregnant breastfeeding . Concurrent severe , intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>refractory metastatic colorectal cancer</keyword>
</DOC>